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SurvivalSummary The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been studied recently in
many cancers. For the first time in a nonendemic region, we have evaluated the prognostic value of TILs in a
whole population–based nationwide cohort of nasopharyngeal carcinoma (NPC) in Finland. A total of 115
cases from Finnish hospitals were included. TILs were analyzed using hematoxylin and eosin–stained slides
according to the criteria of the International Immuno-Oncology BiomarkerWorking Group. TILs were eval-
uated separately in stromal and tumor compartments. The log-rank test and univariable and multivariable
analyses were used to compare survival in patients with tumors with low and high TILs. A significant pos-
itive correlation was observed between the occurrence of intratumoral and stromal TILs (P b .001). In mul-
tivariable analysis, NPC cases with low intratumoral TILs had poor overall survival with a hazard ratio (HR)1 Equal contribution.
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212 A. Almangush et al.of 2.55 and 95% confidence interval (95% CI) of 1.60 to 4.05 (P b .001). Cases with low intratumoral TILs
also had poor disease-specific survival (HR, 2.02; 95% CI, 1.16-3.52; P = .015). Keratinized tumors with
low intratumoral TILs were associated with an even poorer overall survival (HR, 3.94; 95% CI, 2.17-
7.15; P b .001) and a poor disease-specific survival (HR, 2.97; 95% CI, 1.46-6.05; P = .009). Our study
demonstrates that the evaluation of TILs is simple and can be assessed routinely in NPC.
© 2018 Elsevier Inc. All rights reserved.1. Introduction 2. Materials and methodsNasopharyngeal carcinoma (NPC) has a distinct histopathol-
ogy and geographic distribution compared with other cancers of
the head and neck [1,2]. The incidence in Southern China and
Southeast Asia (endemic areas) is high, with most tumors be-
ing undifferentiated, nonkeratinizing carcinomas [3,4]. On
the contrary, NPCs of nonendemic areas (such as Northern Eu-
rope) can be keratinizing or nonkeratinizing [5]. The mortality
rate of NPC in both endemic and nonendemic areas is high
even in cases diagnosed at an early stage [6]. On the basis of
GLOBOCAN worldwide estimates of cancer incidence and
mortality, 86 700 new cases of NPC were diagnosed in 2012
and were associated with 50 800 deaths [1]. As in other can-
cers, variations in clinical outcome of NPC were noted even
between cases diagnosed at the same stage and receiving sim-
ilar treatments [7]. This emphasizes the need to identify
markers that can predict the behavior of an individual NPC.
Such markers would be very important for treatment planning.
For histopathologic diagnosis of NPC, pathologists recog-
nize an infiltrate of lymphocytes and plasma cells between tu-
mor islands, and some of these lymphocytes and plasma cells
penetrate the tumor islands. However, the pathology report of
NPC does not include assessment of the host immune re-
sponse. There is a need to identify reliable histopathologic
markers to evaluate the immune response in routine hematox-
ylin and eosin (HE)–stained slides. Such parameters/markers
could facilitate prediction of patient outcome and assist in
treatment planning. Interestingly, NPC is also known as lym-
phoepithelial carcinoma due to the presence of an abundant
population of nonneoplastic lymphocytes [8]. However, the
number of these lymphocytes varies from one tumor to another
and sometimes also varies between the tumoral and stromal
parts of the same tumor [9].
In various epithelial tumors, tumor-infiltrating lymphocytes
(TILs) infiltrate tumor islands and the associated stroma [10,11].
A recent meta-analysis including different subsites of head
and neck cancers confirmed the prognostic significance of
specific TILs (namely, intratumoral CD3+ and CD8+) [12].
Overall assessment of TILs using routine HE-stained slides
has been recently reported for many cancers [13-15]. How-
ever, there are currently no studies that have evaluated TILs
using routine HE slides in NPCs of nonendemic regions. We
sought to analyze the prognostic significance of TILs in a
Finnish multicenter nationwide cohort of NPC that includes
both keratinizing and nonkeratinizing types.We identified 169 patients treated for NPC at the 5 Finnish
university hospitals (Helsinki, Turku, Tampere, Kuopio, and
Oulu) or in regional central hospitals. All cases were diag-
nosed between 1990 and 2009, and they were staged accord-
ing to the International Union Against Cancer staging
system, seventh edition [16]. There were 115 patients with rep-
resentative HE-stained slides, and all available diagnostic
slides were retrieved for evaluation of TILs. To identify
Epstein-Barr virus (EBV) status in sections of NPC, we used
in situ hybridization for EBV-encoded RNA (Ventana/Roche
Medical Systems, Inc, Tucson, AZ). The study was approved
by the research ethics committee of the Hospital District of
Southwest Finland and the Finnish National Supervisory Au-
thority for Welfare and Health (VALVIRA).
TILs (Fig. 1) were evaluated separately for the tumoral
compartment and the stromal compartment. The quantity of
intratumoral TILs was defined as the percentage of tumor
islands/nests occupied by infiltrating lymphocytes. The quan-
tity of stromal TILs was scored as the percentage of stromal
areas occupied by infiltrating lymphocytes. Stroma not related
to a tumor was not considered. TILs were assessed on HE-
stained diagnostic sections. For evaluation of TILs, we
followed a practical review for pathologists recently intro-
duced by the International Immuno-Oncology Biomarkers
Working Group [17], which classifies TILs into intratumoral
TILs and stromal TILs. We evaluated TILs within the borders
of the invasive tumors, and assessment of the average amount
of TILs was performed as introduced in the recent guidelines
[13]. At least 5fieldswere evaluated to assess the average of TILs.
A training session to familiarize with the scoring criteria
was guided by an experienced head and neck pathologist (I. L.).
An independent researcher (A. A.) scored all cases, and all
scores were then reviewed by the pathologist (I. L.). Another
experienced pathologist (J. H.), who did not participate in
the training session, was invited to score about one-third of
the cohort (45 cases) randomly selected to evaluate the agree-
ment between pathologists.2.1. Data analysis
We used the κ coefficient to evaluate the agreement be-
tween pathologists. The relationship between intratumoral
TILs and the age of the patient, sex, TNM stage, type of
Fig. 1 Representative examples of TILs in NPC from a nonen-
demic region (magnification ×100). A, High TILs, which infiltrate
in both tumor islands and the stroma (HE stain). B, An example of
scarcity of TILs in a case of NPC (HE stain). C, Keratinizing NPC
with low TILs (Van Gieson stain).
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tabulation. The statistical significance of factors associated
with intratumoral TILs was evaluated using the χ2 test.We then analyzed overall survival (OS) and disease-
specific survival (DSS). The date of diagnosis was the starting
point for calculation of survival time. Death from any cause or
from NPC were defined as the events to be studied. We ana-
lyzed the prognostic value of intratumoral TILs (at a 5% cutoff
point), stromal TILs (at a 10% cutoff point), and type of histol-
ogy. Then we designed a histopathologic prognostic model
that includes both intratumoral TILs (low or high) and the type
of histology (keratinizing or nonkeratinizing) as follows: low-
risk (nonkeratinizing tumors with high intratumoral TILs),
intermediate-risk (nonkeratinizing tumors with low intratu-
moral TILs or keratinizing tumors with high intratumoral
TILs), and high-risk (keratinizing tumors with low intratu-
moral TILs). Kaplan-Meier survival curves were drawn sepa-
rately for OS and DSS events by intratumoral TILs, stromal
TILs, and our proposed histopathologic model. The log-rank
test was used to evaluate the statistical significance of differ-
ences between the survival curves.
We estimated multivariable Cox regression models to ver-
ify the effects of significant prognosticators when age and
stage were adjusted. The models were estimated separately
for each prognostic variable. For the models, hazard ratios
(HRs) and 95% confidence intervals (CIs) were reported with
the additional information likelihood ratio test [18]. The as-
sumptions of the Cox regression model were checked graphi-
cally by Kaplan-Meier curves.
We used IBM SPSS Statistics, version 24 (Armonk, NY,
USA) and MedCalc Statistical Software version 17.9.7 (Med-
Calc Software bvba, Ostend, Belgium) for all statistical analy-
ses. A P value of less than .05 was considered statistically
significant.3. Results
The clinicopathological characteristics of our whole popu-
lation–based cohort are summarized in Table 1. The median
follow-up time was 60 months (range, 1-262 months). This
cohort consisted of 80 (69.6%) men and 35 (30.4%) women.
The median age at the time of diagnosis was 58 years (range,
12-85 years). There were 15 (13%) cases in stage I, 29
(25.2%) in stage II, 40 (34.8%) in stage III, and 31 (27%) in
stage IV. Fifty (43.5%) patients were treated with radiother-
apy, 60 (52.2%) patients were treated with chemoradiother-
apy, and 5 (4.3%) patients received palliative treatment. A
total of 75 (65.2%) tumors had high intratumoral TILs and
40 (34.8%) tumors had low intratumoral TILs. For stromal
TILs, 84 (73%) tumors were high and 31 (27%) were low.
There was a moderate agreement between the pathologists
in categorizing the tumors into groups with low or high TILs
(κ value of 0.6).
TILs were noted in most of our cases, with a variation in
percentage from one case to another. Many more TILs were
observed in the stroma compared with the tumor parts. In gen-
eral, the quantity of stromal and intratumoral TILs was posi-
tively correlated with each other (2-sided; P b .001). High
Table 1 Relationship between iTILs with age of patient, sex, TNM stage, EBV status, type of histology, and stromal infiltrating lymphocytes
Variable Total
(n = 115), no. (%)
Low iTILs
(n = 40), no. (%)
High iTILs
(n = 75), no. (%)
P of χ2 test
Age (y) .034
≤58 59 (51.3) 15 (37.5) 44 (58.7)
N58 56 (48.7) 25 (62.5) 31 (41.3)
Sex .832
Male 80 (69.6) 27 (67.5) 53 (70.7)
Female 35 (30.4) 13 (32.5) 22 (29.3)
Stage .423
I-II 44 (38.3) 13 (32.5) 31 (41.3)
III-IV 71 (61.7) 27 (67.5) 44 (58.7)
EBV status a b.001
EBV positive 69 (60.0) 8 (27.6) 61 (92.4)
EBV negative 26 (22.6) 21 (72.4) 5 (7.6)
Type of histology b.001
Keratinizing 28 (24.3) 20 (50.0) 8 (10.7)
Nonkeratinizing differentiated 19 (16.5) 9 (22.5) 10 (13.3)
Nonkeratinizing undifferentiated 68 (59.1) 11 (27.5) 57 (76.0)
Stromal infiltrating lymphocytes b.001
Low 31 (27.0) 20 (50.0) 11 (14.7)
High 84 (73.0) 20 (50.0) 64 (85.3)
Abbreviation: iTILs, intratumoral TILs.
a EBV status was not known for 20 cases (17.4%).
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often in young patients (2-sided; P = .03) and were also
found more often in nonkeratinizing undifferentiated tumors
(2-sided; P b .001). Stromal lymphocytes were associated
with the type of histology (P = .005), whereas association
with patient age was less significant (2-sided, P = .05). There
was no correlation between TILs (either intratumoral or
stromal) with sex or stage (2-sided, P N .05). There was a sig-
nificant association between EBV status and TILs (Table 1),
where EBV-positive tumors had high intratumoral and stromal
TILs (P b .001).
Univariable analysis (Tables 2 and 3, Fig. 2) demonstrated
that low intratumoral TILs were associated with poor OS and
DSS and that the most statistically significant value was found
at the 5% cutoff point. For OS at this cutoff point, an HR of
2.63 (95% CI, 1.67-4.16; P b .001) was reported. For DSS,
the HR was 2.17 (95% CI, 1.25-3.76; P = .006). At the other
cutoff points (10%, 20%, 30%, 40%, 50%, 60%), cases with
low intratumoral TILs had poorer prognosis, but the statistical
values were not significant (data not shown). Tumors with low
stromal TILs were associated with poor OS (HR, 2.04; 95%
CI, 1.26-3.33; P = .004), but the prognostic value was not sta-
tistically significant for DSS (HR, 1.62; 95% CI, 0.89-2.94;
P = .11). We tested different cutoff points (5%, 10%, 20%,
30%, 40%, 50%, 60%, 70%, 80%) to stratify the tumors into
low or high stromal TILs, and the best prognostic value was
at 10%. In the Cox regression model (Tables 2 and 3) for mul-
tivariable analysis, intratumoral TILs showed a significant cor-
relation with OS (HR, 2.55; 95% CI, 1.60-4.05; P b .001) and
DSS (HR, 2.02; 95% CI, 1.16-3.52; P = .015). Although stro-
mal TILs were associated with OS (HR, 1.78; 95% CI, 1.08-2.93; P = .025), the association with DSS was not statistically
significant (HR, 1.37; 95% CI, 0.75-2.53; P = .31).
In univariable analysis, the combination scores of intratu-
moral TILs with type of histology were significantly associ-
ated with poorer OS (HR, 3.40; 95% CI, 1.91-6.07;
P b .001) and poorer DSS (HR, 2.86; 95% CI, 1.42-5.77;
P = .003) for keratinizing tumors with low TILs. In multivar-
iable analysis, a higher score in our prognostic model was
significantly associated with poorer OS (HR, 3.94; 95% CI,
2.17-7.15; P b .001) and DSS (HR, 2.97; 95% CI, 1.46-
6.05; P = .009).
In multivariable analysis, most of the clinicopathological
factors were not useful for prognostication except clinical
stage, which was a significant prognostic factor for OS (HR,
2.12; 95% CI, 1.28-3.50; P = .003) and DSS (HR, 3.53;
95% CI, 1.75-7.10; P b .001). Of note, EBV-negative tumors
had a worse OS (HR, 3.54; 95% CI, 2.00-6.25; P b .001) and
DSS (HR, 2.63; 95% CI, 1.37-5.05; P = .004) than EBV-
positive tumors in the multivariable analysis.4. Discussion
The host immune response has a significant role in the clin-
ical behavior of NPC and in many other cancers. It is well
known that similar tumors at the same stage may have extreme
variations in their immune responses [19]. Consequently, the
immunological heterogeneity of NPCmight be useful for iden-
tifying different prognostic categories. The prognostic impact
of TILs has been recently reported in many cancers [20-23].















Keratinizing 2.34 (1.42-3.86) 2.68 (1.60-4.49)
P = .001 P b .001
EBV status
EBV positive 1 1
EBV negative 4.60 (2.65-7.97) 3.54 (2.00-6.25)
P b .001 P b .001
Intratumoral lymphocytes
High 1 1
Low 2.63 (1.67-4.16) 2.55 (1.60-4.05)
P b .001 P b .001
Intratumoral lymphocytes and
type of histology
Low risk 1 1
Intermediate risk 2.26 (1.32-3.86) 2.09 (1.21-3.60)
High risk 3.40 (1.91-6.07) 3.94 (2.17-7.15)
P b .001 P b .001
Stromal lymphocytes
High 1 1
Low 2.04 (1.26-3.33) 1.78 (1.08-2.93)
P = .004 P = .025
Age (y)
≤58 1 1 1 1 1 1
N58 1.88 (1.19-2.97) 2.20 (1.38-3.51) 1.89 (1.08-3.31) 2.02 (1.26-3.22) 2.15 (1.34-3.45) 1.92 (1.20-3.08)
P = .007 P = .001 P = .025 P = .003 P = .002 P = .007
Stage
I-II 1 1 1 1 1 1
III-IV 2.02 (1.23-3.31) 2.33 (1.41-3.85) 1.87 (1.07-3.28) 2.21 (1.34-3.65) 2.32 (1.40-3.86) 2.12 (1.28-3.50)
P = .006 P = .001 P = .028 P = .002 P = .001 P = .003
215Tumor-infiltrating lymphocytes in nasopharyngeal cancerHere, we visually assessed TILs in NPC using HE-stained di-
agnostic slides. This method is simple and has the potential to
successfully assess the behavioral pattern of NPC and even to
predict survival.
We noted that intratumoral TILs are significantly associ-
ated with both OS and cancer-related mortality (ie, DSS).
However, although there was an association between stromal
TILs and survival, this was statistically significant for OS but
not significant for DSS. Similarly, in a study of ovarian cancer,
James et al [14] found an association between prognosis and
both intratumoral and stromal TILs, but the relationship was
statistically significant for intratumoral TILs only. Notably, a
recent Chinese study byWang et al [15] from an endemic area
showed that TILs, specifically stromal TILs, are a promising
prognostic factor for NPC. It is important to note that all their
cases were nonkeratinizing undifferentiated NPCs [15]. We
emphasize that our NPC cases from a nonendemic area are his-
topathologically different including both keratinizing and non-
keratinizing types. Biological distinctions between our cohort
and that of Wang et al [15] might also exist, as development
of NPC in endemic regions is thought to be associated with eti-
ologic factors different from those in nonendemic regions [24].TILs in NPC have been studied recently using immunohisto-
chemistry [25,26]. However, assessment of TILs using just HE
staining is an attractive and simple alternative, which has been
used in evaluating TILs in various cancers [13,22,27]. Evaluation
of TILs usingHE-stained slides was easily applicable in this study
and in previous studies that also reported good reproducibility be-
tween pathologists [10,27,28]. These 2 advantages (routine
staining method and good reproducibility) make TILs a candi-
date eligible to be included in pathology reports of NPC.
In this study, we assessed the number of TILs semiquantita-
tively as a continuous variable according to the recommendation
of the International Immuno-Oncology Biomarkers Working
Group, which has defined no risk threshold between high and
low amount of TILs inNPC [17]. Therefore, we have tested dif-
ferent cutoff points (5%, 10%, 20%, etc) to sort out tumors
with low or high TILs. The highest prognostic significance
of intratumoral TILs for both OS and DSS was reported with
a cutoff point at 5%. This cutoff point was recently identified
as the optimal cutoff point in colorectal cancer [29]. Moreover,
in a recent study of lung cancer, tumors with TILs of 5% or
less had the worst OS and DSS [27]. Digital imaging systems
have the potential of high accuracy and reproducibility.















Keratinizing 2.26 (1.26-4.08) 2.55 (1.60-4.05)
P = .007 P = .009
EBV status
EBV positive 1 1
EBV negative 3.37 (1.78-6.38) 2.63 (1.37-5.05)
P b .001 P = .004
Intratumoral lymphocytes
High 1 1
Low 2.17 (1.25-3.76) 2.02 (1.16-3.52)
P = .006 P = .015
Intratumoral lymphocytes and
type of histology
Low risk 1 1
Intermediate risk 2.17 (1.42-5.77) 1.91 (0.99-3.64)
High risk 2.86 (1.42-5.77) 2.97 (1.46-6.05)
P = .003 P = .009
Stromal lymphocytes
High 1 1
Low 1.62 (0.89-2.94) 1.37 (0.75-2.53)
P = .11 P = .309
Age (y)
≤58 1 1 1 1 1 1
N58 1.43 (0.83-2.47) 1.66 (0.96-2.89) 1.56 (0.83-2.94) 1.57 (0.90-2.73) 1.60 (0.91-2.79) 1.56 (0.89-2.74)
P = .2 P = .071 P = .17 P = .114 P = .102 P = .123
Stage
I-II 1 1 1 1 1 1
III-IV 3.39 (1.69-6.78) 3.64 (1.81-7.32) 3.87 (1.76-8.50) 3.56 (1.77-7.17) 3.59 (1.78-7.26) 3.53 (1.75-7.10)
P = .001 P b .001 P = .001 P b .001 P b .001 P b .001
216 A. Almangush et al.Therefore, they could be considered for further assessment of
TILs in NPC.
The International Immuno-Oncology Biomarkers Working
Group [17] recently published a practical review for patholo-
gists and proposed to standardize the method of assessing TILs
in different tumors, including those of the head and neck re-
gion. They explained that the preexisting lymphoid stroma
can complicate the evaluation of stromal TILs in some head
and neck tumors, and therefore, it is better to focus on intratu-
moral TILs [17]. Such anatomic circumstances might explain
why stromal TILs were not significantly associated with
NPC-related mortality in our cohort. Therefore, we suggest
the reporting of intratumoral TILs in NPC.
Our results identified a group of NPC cases that are at high
risk of cancer-related mortality. Patients in this group have a
keratinizing tumor with a low amount of intratumoral TILs.
Of note, the combination of these 2 features has prognostic
power superior to each one individually. Our proposed model
has the potential to help clinicians in treatment planning and
recommends the choice of multimodality approach for such
NPC cases. The standard treatment of radiotherapy may not
be sufficient for those cases. A more aggressive treatment(eg, definitive chemoradiotherapy and neck dissection for re-
sidual neck disease) might be necessary for keratinizing tu-
mors with low intratumoral TILs. Recent research has
highlighted the usefulness of immunotherapy for some cancers
[30,31], and further research is necessary to evaluate the ben-
efits of such therapies for NPC with low intratumoral TILs.
Recent studies on different cancers have reported a signifi-
cant association between improved survival and high TILs
[21,27,32]. However, the exact mechanism by which TILs af-
fect the prognosis is not well understood. Generally, the pre-
dominance of TILs has been claimed to reflect an effective
antitumor immune response [33,34]. Delayed tumor progres-
sion due to high TILs was also suggested [35]. Of note, pro-
gression of many cancers was accompanied by severe
immune suppression [36]. Such insights indicate that an in-
crease in TILs will enhance antitumor activities improving sur-
vival. Amore specific speculation suggested that suppression of
the epithelial-mesenchymal transition in breast cancer with eri-
bulin chemotherapy can enhance the immune response against
the tumor by improving the cancer immune microenvironment
[37]. Therefore, TILs can be used to monitor the host immune
response to cancer and to predict therapeutic efficacy [37].
Fig. 2 Kaplan-Meier curves describing OS (A, C and E) and DSS (B, D and F) during the follow-up period of NPC. A, OS according to iTILs.
B, DSS according to iTILs. C, OS according to sTILs. D: DSS according to sTILs. E, OS according to our proposed model. F, DSS according to
our proposed model. Abbreviations: iTILs, intratumoral TILs; sTILs, stromal TILs.
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218 A. Almangush et al.One limitation of our study is the small number of cases, de-
spite being a nationwide study. This is because NPC is an un-
common tumor in nonendemic areas such as Finland. For
larger cohorts, further research should involve international col-
laborative efforts from other nonendemic regions. Moreover,
our study did not provide any evidence on how TILs influence
NPC. Also, our study is retrospective, and prospective studies
would be needed before TILs can be included in daily practice
as a factor determining survival. Despite these limitations,
our findings from a nonendemic region (Finland) and recent
findings [15] in an endemic region (China) strongly indicate
that evaluation of TILs can be easily performed in routine
HE-stained slides and has a significant value in assessing
survival.References
[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global
cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
[2] Wei KR, Xu Y, Liu J, Zhang WJ, Liang ZH. Histopathological classifi-
cation of nasopharyngeal carcinoma. Asian Pac J Cancer Prev 2011;12:
1141-7.
[3] Huang WB, Chan JYW, Liu DL. Human papillomavirus and World
Health Organization type III nasopharyngeal carcinoma: multicenter
study from an endemic area in Southern China. Cancer 2018;124:530-6.
[4] El-Naggar AK, Chan JKC, Takata T, Grandis JR, Slootweg PJ. The
fourth edition of the head and neck World Health Organization blue
book: editors’ perspectives. HUM PATHOL 2017;66:10-2.
[5] Ruuskanen M, Grenman R, Leivo I, et al. Outcome of nasopharyngeal
carcinoma in Finland: a nationwide study. Acta Oncol 2018;57:251-6.
[6] Lee AW, NgWT, Chan YH, Sze H, Chan C, Lam TH. The battle against
nasopharyngeal cancer. Radiother Oncol 2012;104:272-8.
[7] Zhang XK, Xu M, Chen JW, et al. The prognostic significance of
tyrosine-protein phosphatase nonreceptor type 12 expression in nasopha-
ryngeal carcinoma. Tumour Biol 2015;36:5201-8.
[8] Applebaum EL, Mantravadi P, Haas R. Lymphoepithelioma of the naso-
pharynx. Laryngoscope 1982;92:510-514.
[9] Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pages F. Ra-
tional bases for the use of the immunoscore in routine clinical settings
as a prognostic and predictive biomarker in cancer patients. Int Immunol
2016;28:373-82.
[10] Tramm T, Di Caterino T, Jylling AB, et al. Standardized assessment of
tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-
observer agreement between pathologists. Acta Oncol 2018;57:90-4.
[11] Badalamenti G, Fanale D, Incorvaia L, et al. Role of tumor-infiltrating
lymphocytes in patients with solid tumors: can a drop dig a stone? Cell
Immunol 2018 [Epub ahead of print].
[12] de Ruiter EJ, Ooft ML, Devriese LA, Willems SM. The prognostic role
of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the
head and neck: a systematic review andmeta-analysis. Oncoimmunology
2017;6:e1356148.
[13] Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-
infiltrating lymphocytes (TILs) in breast cancer: recommendations
by an International TILs Working Group 2014. Ann Oncol 2015;26:
259-71.
[14] James FR, Jiminez-Linan M, Alsop J, et al. Association between tumour
infiltrating lymphocytes, histotype and clinical outcome in epithelial
ovarian cancer. BMC Cancer 2017;17:657.
[15] Wang YQ, Chen YP, Zhang Y, et al. Prognostic significance of tumor-
infiltrating lymphocytes in non-disseminated nasopharyngeal carci-
noma: a large-scale cohort study. Int J Cancer 2018 Jun 15;142(12):
2558-66.[16] Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of
Malignant Tumours. Hoboken, United Kingdom: John Wiley & Sons,
Incorporated; 2009.
[17] Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lym-
phocytes in solid tumors: a practical review for pathologists and proposal
for a standardizedmethod from the International Immuno-Oncology Bio-
markers Working Group: part 2: TILs in melanoma, gastrointestinal tract
carcinomas, non-small cell lung carcinoma and mesothelioma, endome-
trial and ovarian carcinomas, squamous cell carcinoma of the head and
neck, genitourinary carcinomas, and primary brain tumors. Adv Anat
Pathol 2017;24:311-35.
[18] Kleinbaum DG, Klein M. Survival Analysis: A Self-learning Text. 2nd
ed. New York: Springer Science, Business Media, LLC; 2005.
[19] Galon J, Pages F, Marincola FM, et al. Cancer classification using the
Immunoscore: a worldwide task force. J Transl Med 2012;10:205.
[20] Buisseret L, Desmedt C, Garaud S, et al. Reliability of tumor-infiltrating
lymphocyte and tertiary lymphoid structure assessment in human breast
cancer. Mod Pathol 2017;30:1204-12.
[21] Stein AV, Dislich B, Blank A, et al. High intratumoural but not peritu-
moural inflammatory host response is associated with better prognosis
in primary resected oesophageal adenocarcinomas. Pathology 2017;49:
30-7.
[22] Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte
grade is an independent predictor of sentinel lymph node status and sur-
vival in patients with cutaneous melanoma. J Clin Oncol 2012;30:
2678-83.
[23] Huh JW, Lee JH, Kim HR. Prognostic significance of tumor-infiltrating
lymphocytes for patients with colorectal cancer. Arch Surg 2012;147:
366-72.
[24] Sung NS, Edwards RH, Seillier-Moiseiwitsch F, Perkins AG, Zeng Y,
Raab-Traub N. Epstein-Barr virus strain variation in nasopharyngeal car-
cinoma from the endemic and non-endemic regions of China. Int J Can-
cer 1998;76:207-15.
[25] Ooft ML, van Ipenburg JA, Braunius WW, Zuur CI, Koljenovic S, Will-
ems SM. Prognostic role of tumor infiltrating lymphocytes in EBVpositive
and EBV negative nasopharyngeal carcinoma. Oral Oncol 2017;71:16-25.
[26] Larbcharoensub N, Mahaprom K, Jiarpinitnun C, et al. Characterization
of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte
in Epstein-Barr virus–associated nasopharyngeal carcinoma. Am J Clin
Oncol 2018 [Epub ahead of print].
[27] Rakaee M, Kilvaer TK, Dalen SM, et al. Evaluation of tumor-infiltrating
lymphocytes using routine H&E slides predicts patient survival in
resected non–small cell lung cancer. HUM PATHOL September 2018;79:
188-98.
[28] Swisher SK, Wu Y, Castaneda CA, et al. Interobserver agreement be-
tween pathologists assessing tumor-infiltrating lymphocytes (TILs) in
breast cancer using methodology proposed by the International TILs
Working Group. Ann Surg Oncol 2016;23:2242-8.
[29] Lang-Schwarz C, Melcher B, Haumaier F, et al. Budding and tumor in-
filtrating lymphocytes—combination of both parameters predicts sur-
vival in colorectal cancer and leads to new prognostic subgroups. HUM
PATHOL September 2018;79:160-7.
[30] Ilie M, Benzaquen J, Hofman V, et al. Immunotherapy in non-small
cell lung cancer: biological principles and future opportunities.
Curr Mol Med 2017;17(8):527-40. https://doi.org/10.2174/
1566524018666180222114038.
[31] Toh JWT, de Souza P, Lim SH, et al. The potential value of
immunotherapy in colorectal cancers: review of the evidence for pro-
grammed death-1 inhibitor therapy. Clin Colorectal Cancer 2016;15:
285-91.
[32] Kojima YA,WangX, Sun H, Compton F, CovinskyM, Zhang S. Repro-
ducible evaluation of tumor-infiltrating lymphocytes (TILs) using the
recommendations of International TILs Working Group 2014. Ann
Diagn Pathol 2018;35:77-9.
[33] Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Frid-
man WH. Immune infiltration in human tumors: a prognostic factor that
should not be ignored. Oncogene 2010;29:1093-102.
219Tumor-infiltrating lymphocytes in nasopharyngeal cancer[34] Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity
in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol 2016;13:
228-41.
[35] Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The
prognostic influence of tumour-infiltrating lymphocytes in cancer: a
systematic review with meta-analysis. Br J Cancer 2011;105:93-103.[36] Finn OJ. Immuno-oncology: understanding the function and dysfunc-
tion of the immune system in cancer. Ann Oncol 2012;23(Suppl. 8):
viii6-9.
[37] Kashiwagi S, Asano Y, Goto W, et al. Use of tumor-infiltrating lympho-
cytes (TILs) to predict the treatment response to eribulin chemotherapy in
breast cancer. PLoS One 2017;12:e0170634.
